CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Major Shareholder Sells $179,934.48 in Stock

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) major shareholder Bioventures Opportunities G. Yk sold 2,998,908 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $0.06, for a total value of $179,934.48. Following the completion of the sale, the insider now directly owns 13,005,169 shares of the company’s stock, valued at $780,310.14. This trade represents a 18.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

CERo Therapeutics Trading Down 18.5 %

Shares of CERO opened at $0.06 on Monday. The business’s fifty day moving average is $0.13 and its 200 day moving average is $0.21. CERo Therapeutics Holdings, Inc. has a 12-month low of $0.06 and a 12-month high of $12.80.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.